Srs Capital Advisors, Inc. Esperion Therapeutics, Inc. Transaction History
Srs Capital Advisors, Inc.
- $8.6 Billion
- Q3 2025
A detailed history of Srs Capital Advisors, Inc. transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 7,750 shares of ESPR stock, worth $22,475. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,750Holding current value
$22,475% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ESPR
# of Institutions
214Shares Held
114MCall Options Held
643KPut Options Held
769K-
Black Rock Inc. New York, NY14MShares$40.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.1MShares$35.1 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY9.75MShares$28.3 Million0.51% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT7.06MShares$20.5 Million0.1% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$19.4 Million7.68% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $193M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...